Radioimmunoconjugates for treating cancer: recent advances and current opportunities.

about

Technetium-99m based small molecule radiopharmaceuticals and radiotracers targeting inflammation and infection.

P2860

Q40084585-827CDEE0-D773-41D1-912A-07E3FD3AD18F

P2860

Radioimmunoconjugates for treating cancer: recent advances and current opportunities.

Item

http://www.wikidata.org/entity/Q38691472

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Radioimmunoconjugates for treating cancer: recent advances and current opportunities.

@en

type

Item

label

Radioimmunoconjugates for treating cancer: recent advances and current opportunities.

@en

prefLabel

Radioimmunoconjugates for treating cancer: recent advances and current opportunities.

@en

P1476

Radioimmunoconjugates for treating cancer: recent advances and current opportunities.

@en

P2093

François Guerard

http://www.w3.org/2001/XMLSchema#string

Mathieu Frindel

http://www.w3.org/2001/XMLSchema#string

Michel Chérel

http://www.w3.org/2001/XMLSchema#string

P2860

Continuous cultures of fused cells secreting antibody of predefined specificity

High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial.

[Therapeutic monoclonal antibodies: a little history, a lot of engineering, and... some clinical successes]

Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.

Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab.

Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial.

Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6

Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody

P304

813-819

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14712598.2017.1322577

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Françoise Kraeber-Bodéré

P577

2017-04-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28438082

http://www.w3.org/2001/XMLSchema#string

Radioimmunoconjugates for treating cancer: recent advances and current opportunities.

about

P2860

P2860

Radioimmunoconjugates for treating cancer: recent advances and current opportunities.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698